Henderson Jane 4

What Happened Jane Henderson, Chief Financial Officer of Apogee Therapeutics (APGE), sold a total of 2,000 common shares in open-market transactions on April 1, 2026. The sales consisted of 900 shares at a weighted-average price of $84.46 (proceeds $76,014) and 1,100 shares at a weighted-average price of $85.46 (proceeds $94,006), for aggregate proceeds of approximately $170,020. These were outright sales (transaction code S) rather than purchases.

Key Details

• Transaction dates: April 1, 2026; Form 4 filed April 3, 2026 (timely).
• Sales: 900 shares @ $84.46 (weighted avg; prices in range $84.15–$85.05) and 1,100 shares @ $85.46 (weighted avg; prices in range $85.17–$85.79).
• Total proceeds: ~$170,020.
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnotes: (F1) Trades executed pursuant to a Rule 10b5-1 trading plan adopted Sept 2, 2025. (F2/F3) Reported prices are weighted averages across multiple executions; Henderson will provide a per-trade breakdown on request.
• Filing timeliness: Filed within the normal Form 4 reporting window (no late filing flag).

Context Sales made under a pre-established Rule 10b5-1 plan are typically scheduled in advance and are considered routine; they do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases can be more informative about insider conviction, while planned sales like these are commonly used for diversification or liquidity.